Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matasar, Matthew; Capra, Marcelo; ÖZCAN, MUHİT; Lv, Fangfang; Li, Wei; Yanez, Eduardo; Sapunarova, Katya; Lin, Tongyu; Jin, Jie; Jurczak, Wojciech; Hamed, Aryan; Wang, Ming-Chung; Baker, Ross; Bondarenko, Igor; Zhang, Qingyuan; Feng, Jifeng; Geissler, Klaus; Lazaroiu, Mihaela; SAYDAM, GÜRAY; Szomor, Arpad; Bouabdallah, Krimo; Galiulin, Rinat; Uchida, Toshiki; Soler, Lidia; Cao, Anjun; Hiemeyer, Florian; Mehra, Aruna; Childs, Barrett; Shi, Yuankai; Zinzani, Pier

doi:10.1016/s1470-2045(21)00145-5

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Atıf İçin Kopyala

Matasar M. J., Capra M., ÖZCAN M., Lv F., Li W., Yanez E., ...Daha Fazla

LANCET ONCOLOGY, cilt.22, sa.5, ss.678-689, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22 Sayı: 5
Basım Tarihi: 2021
Doi Numarası: 10.1016/s1470-2045(21)00145-5
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.678-689
Ankara Üniversitesi Adresli: Evet

Özet

Background Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety as monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma who had received at least two therapies. The CHRONOS-3 study aimed to assess the efficacy and safety of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.